Identifying populations at risk may provide opportunities for primary prevention.
Hypertension goes up more than with celecoxib in patients who are at increased risk for cardiovascular disease.
Ambrisentan and tadalafil as one lowers risk of clinical failure in patients with pulmonary arterial hypertension.
Contrave, a combination of naltrexone and buproprion, has been approved for long-term weight loss management in overweight and obese adults.
Ambulatory blood pressure monitoring is a useful prognosis tool to differentiate between true and white coat resistant hypertension, according to a study published online March 28 in Hypertension.